Showing 4121-4130 of 5307 results for "".
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly
- FDA Accepts BLA for Bimekizumab for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-bla-for-bimekizumab-for-plaque-psoriasis/2460536/The FDA and the European Medicines Agency (EMA) have accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), respectively, for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. “After a series of positive Phas
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- Lilly Launches Digital Health Open Innovation Challenge to Help Transform AD Carehttps://practicaldermatology.com/news/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-ad-care/2460529/Eli Lilly and Company is launching an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions to help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Der
- Cynosure Taps Consumer Products Vet Anne Gates for Its Board of Directorshttps://practicaldermatology.com/news/cynosure-taps-consumer-products-veteran-anne-gates-for-its-board-of-directors/2460525/Anne Gates, former President at MGA Entertainment and Executive Vice President and CFO of The Walt Disney Company's Consumer Products Division, has joined Cynosure’s board of directors and will chair the company's audit committee. "Anne brings with her a wealth o
- Partner Therapeutics Moves Ahead with Phase 3 Study of Leukine Plus Ipilumimab and Nivolumab for Melanomahttps://practicaldermatology.com/news/partner-therapeutics-moves-ahead-with-phase-3-study-of-leukine-plus-ipilumimab-and-nivolumab-for-melanoma/2460524/Partner Therapeutics, Inc. is resuming enrollment in the National Cancer Institute (NCI)-sponsored ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) study of Leukine plus Ipilumimab and Nivolumab for Melanoma following a successful planned interim analysis. EA6141 (
- Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://practicaldermatology.com/news/dr-doris-day-joins-nufabrxs-ad-board/2460523/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredients into fabrics to 
- ICYMI: ASA Honors Drs. Doris Day and Mark Lebwohl at Virtual Galahttps://practicaldermatology.com/news/icymi-asa-honors-drs-doris-day-and-mark-lebwohl-at-virtual-gala/2460521/Dermatologists Drs. Doris Day and Mark Lebwohl took home top awards at the American Skin Association’s (ASA) annual gala, which was held virtually this year. Dr. Day, a clinical associate professor of dermatology at NYU Langone Medical Center, received ASA's Excellen
- Arcutis to Accelerate Program for ARQ-151 for Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-to-accelerate-program-for-arq-151-for-atopic-dermatitis/2460520/Arcutis Biotherapeutics, Inc. plans to advance its program to develop ARQ-151 (topical roflumilast cream) for the treatment of atopic dermatitis into Phase 3 clinical trials without conducting the previously planned Phase 2b atopic dermatitis trial. The decision follows an End